Drug Profile
Fasinumab - Mitsubishi Tanabe Pharma/Regeneron/Teva
Alternative Names: MT-5547; REGN 475; SAR 164877Latest Information Update: 10 Nov 2022
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; sanofi-aventis
- Developer Mitsubishi Tanabe Pharma Corporation; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries
- Class Monoclonal antibodies; Non-opioid analgesics
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Back pain; Pain
Most Recent Events
- 10 Nov 2022 Discontinued - Phase-III for Pain in Japan (SC) (Mitsubishi Tanabe Pharma pipeline, November 2022)
- 10 Feb 2022 Mitsubishi Tanabe Pharma Corporation plans to launch fasinumab for Pain in Japan in 2023
- 07 Feb 2022 Phase-III clinical trials in Pain in Japan (SC) (Mitsubishi Tanabe Pharma pipeline, February 2022)